The FDA may be falling behind its schedule for implementing a national drug tracking system intended to prevent counterfeit and substandard medicines from entering the supply chain.
Drug distributors and pharmacists told me the implementation of the tracking system has been slow and the Food and Drug Administration is behind on issuing guidance needed by industry. The Drug Supply Chain Security Act (DSCSA) outlines critical steps to build an electronic, interoperable system to identify and trace certain prescription drugs within the U.S. by 2023. The DSCSA is part of the Drug Quality and Security Act (Pub. L. No. 113-54), signed into law in November 2013.
As well as keeping counterfeit drugs from entering the supply chain, the system also is intended to prevent the diversion of legitimate drug products for illegal use and the importation of unapproved drugs. The goal is to keep dangerous drugs that could harm patients from entering the drug supply chain. This is a big challenge as about 4 billion prescriptions were filled at U.S. retail pharmacies in 2016, according to the FDA’s website.
The Healthcare Distribution Alliance (HDA) is concerned about whether the 2023 deadline for implementation will be met without specific directions from the FDA on how to do it, Patrick Kelly, executive vice president of government affairs at the HDA, told me. The HDA represents wholesale distributors that purchase drugs from manufacturers and sell them to pharmacies, hospitals, and others.
Also, Jenna Ventresca, director of health policy at the American Pharmacists Association (APhA), told me she doesn’t think the 2023 deadline “is reasonable anymore. The compliance time is very short given the size of the task, issues that have arisen in current compliance efforts, and delays that have already occurred.”
Lyndsay Meyer, an FDA press officer, told Bloomberg BNA in a Sept. 25 email that “implementation of DSCSA is a high priority in the agency and we have no concerns about being able to implement the system by 2023.” The agency has issued some guidance documents on topics such as how to exchange product tracing information and identifying suspect products. Also, in July, the FDA announced plans to hold three public meetings intended to give pharmaceutical supply chain members an opportunity to provide input on strategies and issues related to the enhanced drug distribution security provisions of the DSCSA. The agency held the first meeting in August, and will hold two additional meetings in December and in February 2018.
But Kelly said wholesale distributors are still waiting for more guidance that the agency was supposed to issue in 2015. Specifically, he said the FDA was supposed to provide guidance on how pharmaceutical distributors should be licensed by the states and how to handle drug products that don’t have serial numbers.
All pharmaceutical distributors must be licensed by the state in which they are located. Under the DSCSA, the FDA is statutorily required to publish model state licensure standards that factor in requirements pertaining to serialized products, obligations to keep and maintain records of transaction information, product storage, and other appropriate specifications.
The second guidance deals with how to handle grandfathered products that don’t have serial numbers, Kelly said. “After the serialized products come on the market, you’re still going to have a marketplace full of unserialized product that is valid, legitimate product but is essentially noncompliant” with the DSCSA. Pulling all of those products off the market could create drug shortages, he said.
Read my full article here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)